kabutan

ReproCELL Incorporated(4978) Summary

4978
TSE Growth
ReproCELL Incorporated
159
JPY
-3
(-1.85%)
Dec 5, 12:47 pm JST
1.01
USD
Dec 4, 10:49 pm EST
Result
PTS
outside of trading hours
158.7
Dec 5, 12:49 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.74
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
162 JPY 1.04 USD
Previous Close Dec 4
162 JPY 1.04 USD
High Dec 5, 9:02 am
163 JPY 1.05 USD
Low Dec 5, 12:37 pm
158 JPY 1.01 USD
Volume
345,500
Trading Value
0.06B JPY 0.36M USD
VWAP
160.95 JPY 1.04 USD
Minimum Trading Value
15,900 JPY 101 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
160
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,020
1-Year High Feb 6, 2025
31,812
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 5,210,600
Nov 21, 2025 0 5,310,000
Nov 14, 2025 0 5,477,300
Nov 7, 2025 0 5,574,300
Oct 31, 2025 0 5,462,200
Company Profile
ReproCELL Incorporated is a biotech venture company specializing in iPS cell-related research reagents, collaborating with the University of Tokyo and Kyoto University. The company also offers contract manufacturing services.
Sector
Chemicals
ReproCELL Incorporated develops businesses centered on iPS cell-related technologies. In its research support division, the company manufactures and sells research products, provides research outsourcing services, and distributes cell measurement equipment. The medical division focuses on regenerative medicine research and development, contract manufacturing of iPS cell regenerative medicine products, and clinical testing services. Currently, ReproCELL is developing three regenerative medicine products: StemCaimal, iPS neural glial cells, and tumor-infiltrating lymphocyte infusion therapy. The company's strength lies in its RNA reprogramming technology, which enables the creation of highly safe iPS cells.